AbbVie keeps Humira market share near 100% despite biosimilars: report [Seeking Alpha]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Seeking Alpha
U.S. market entry of vastly discounted biosimilars more than a year ago, according to a report from generic drugmaker Samsung Bioepis. In its latest quarterly biosimilar report, the South Korean company said that as of February 2024, AbbVie ( ABBV ) had retained 96% of the adalimumab market share, a year after the launch of the first off-patent version of the drug in the U.S. Amgen ( NASDAQ: AMGN ) rolled out the first biosimilar against Humira in the U.S. last year with the launch of Amjevita/Amgevita in late January. Several other copycat versions from companies such as Novartis' ( NVS ) spinoff Sandoz ( OTCQX:SDZNY OTCQX:SDZXF ), Coherus BioSciences ( CHRS ), Fresenius ( OTCPK:FSNUF OTCPK:FSNUY ), Organon ( NYSE: OGN )/Samsung Bioepis, and Pfizer ( PFE ) followed suit. Others, such as Viatris ( VTRS ), have yet to finalize their launch dates. Most recently, generic drugmakers Teva Pharmaceuticals ( NYSE: TEVA ) and Alvotech ( ALVO ) won U.S. approval for their Humira biosim
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTSPR Newswire
- What's in the Cards for Amgen (AMGN) This Earnings Season? [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCYPR Newswire
- Biologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033 [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- AMGN's page on the SEC website